MaxCyte outlines $30M-$32M 2026 revenue target as ExPERT DTx launch and SPL milestones drive outlook
Source: SeekingAlpha
2026-03-25 02:15:34 ET
More on MaxCyte
- MaxCyte, Inc. (MXCT) Q4 2025 Earnings Call Transcript
- MaxCyte GAAP EPS of -$0.09 misses by $0.01, revenue of $7.3M misses by $1.86M
- Quant snapshot: AAR, Noah Holdings lead strong buys as Blaize, Fractyl Health lag
- Seeking Alpha’s Quant Rating on MaxCyte
- Historical earnings data for MaxCyte
Read the full article on Seeking Alpha
For further details see:
MaxCyte outlines $30M–$32M 2026 revenue target as ExPERT DTx launch and SPL milestones drive outlook
MaxCyte Inc.
NASDAQ: MXCT
MXCT Trading
27.25% G/L:
$1.04 Last:
5,900,426 Volume:
$0.9401 Open:
MXCT Latest News
May 12, 2026 04:05:00 pm
MaxCyte Reports First Quarter 2026 Financial Results and Reiterates Full Year 2026 Guidance
MXCT Stock Data
$82,138,988
103,153,769
1.05%
195
N/A
Biotechnology & Life Sciences
Healthcare
US
Rockville
